Achilles Therapeutics Plc ADR (NASDAQ: ACHL) is 21.93% higher on its value in year-to-date trading and has touched a low of $0.63 and a high of $1.76 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ACHL stock was last observed hovering at around $1.39 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $1.39, the stock is 17.46% and 24.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.42 million and changing 0.00% at the moment leaves the stock 48.43% off its SMA200. ACHL registered 41.84% gain for a year compared to 6-month gain of 78.37%. The firm has a 50-day simple moving average (SMA 50) of $1.10662 and a 200-day simple moving average (SMA200) of $0.93345.
The stock witnessed a 19.83% loss in the last 1 month and extending the period to 3 months gives it a 35.61%, and is 24.11% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.99% over the week and 3.43% over the month.
Achilles Therapeutics Plc ADR (ACHL) has around 215 employees, a market worth around $57.13M and $0.00M in sales. Distance from 52-week low is 120.63% and -21.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-65.21%).
The EPS is expected to grow by 89.66% this year
The shares outstanding are 41.10M, and float is at 37.95M with Short Float at 0.32%.
The top institutional shareholder in the company is SYNCONA PORTFOLIO LTD with over 11.09 million shares valued at $9.04 million. The investor’s holdings represent 27.5236 of the ACHL Shares outstanding. As of 2024-06-30, the second largest holder is FCPM III SERVICES B.V. with 2.39 million shares valued at $1.95 million to account for 5.9334 of the shares outstanding. The other top investors are REDMILE GROUP, LLC which holds 1.61 million shares representing 3.9921 and valued at over $1.31 million, while VESTAL POINT CAPITAL, LP holds 3.7238 of the shares totaling 1.5 million with a market value of $1.22 million.
Achilles Therapeutics Plc ADR (ACHL) Insider Activity
Still, SEC filings show that on Feb 04 ’25, O’Neill Julie (Former Director) Proposed Sale 25,000 shares at an average price of $1.37 for $34250.0. The insider now directly holds shares of Achilles Therapeutics Plc ADR (ACHL).
